Login to Your Account

Week in Review

Monday, December 12, 2011


Dendreon Corp. raised $125 million by monetizing its share of royalties on Victrelis (boceprevir).

EMBL Ventures GmbH closed a $53.5 million fund for German life science companies.

Forbion Capital Partners closed its second FCF 1 Co-Investment Fund at about $50 million.

Gilead Sciences Inc. priced $3.7 billion worth of senior unsecured notes in a public offering.


To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription